Focused On-demand Library for DnaJ homolog subfamily C member 24

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6P3W2

UPID:

DJC24_HUMAN

Alternative names:

CSL-type zinc finger-containing protein 3; Diphthamide biosynthesis protein 4

Alternative UPACC:

Q6P3W2; A8K0V0; B1ALC1; I6L9B4

Background:

DnaJ homolog subfamily C member 24, also known as CSL-type zinc finger-containing protein 3 and Diphthamide biosynthesis protein 4, is pivotal in stimulating the ATPase activity of Hsp70-type chaperones. Its function is notably enhanced by iron-binding, with the iron-bound form being redox-active and serving as an electron carrier. This protein is integral to the diphthamide biosynthesis process, a unique post-translational modification of histidine in translation elongation factor 2 (EEF2), which is a target for toxins like diphtheria toxin and Pseudomonas exotoxin A.

Therapeutic significance:

Understanding the role of DnaJ homolog subfamily C member 24 could open doors to potential therapeutic strategies.